Market Access Consulting

End-to-End Market Access Consulting for Life Sciences, Health Foods, Industrial and Consumer Goods.

At Cisema, we deliver comprehensive market access consulting services tailored to the unique requirements of pharmaceutical, biotech, medical device, veterinary, cosmetic, health food, and industrial goods companies. Our mission is to help you overcome access challenges, unlock coverage decisions, and drive commercial success in China and across Asia Pacific markets.

Market access consulting
Market access strategy

Market Access Consulting for
Pharma & Biotech

Successfully entering the pharmaceutical and biotech markets in Asia Pacific requires more than regulatory approval; it demands a strategic, data-driven approach. Cisema supports your product journey with integrated market access solutions that combine regulatory and clinical strategy, health economics real-world evidence and payers insights. Our goal is to accelerate access, ensure compliance and optimize patient outcomes while aligning with market dynamics and stakeholder expectations.

Regulatory & Access Intelligence

Stay ahead of evolving market dynamics with timely, actionable insights. We continuously monitor Health Technology Assessment (HTA) developments, pricing frameworks, coverage decisions, and policy updates across China and the Asia Pacific region to keep your market access strategy informed and competitive.

Pricing & Reimbursement Strategy

We develop locally tailored pricing strategies grounded in clinical evidence, real world data, and health economics modeling. Our team ensures alignment with payer expectations across systems such as China’s National Reimbursement Drug List (NRDL) and Provincial Reimbursement Drug List (PRDL), and regional listing frameworks.

Health Economics & Outcomes Research (HEOR)

Demonstrate product value through rigorous economic modeling. Our experts develop cost-effectiveness analysis, budget impact models, and comparative studies aligned with local Health Technology Assessment (HTA) requirements to support reimbursement and coverage decisions.

Reimbursement Dossier Preparation

Accelerate market access with comprehensive, high-quality dossiers. We compile clinical trial data, real world outcomes, and local market intelligence to support early engagement with payers and secure listing approvals.

Market Entry & Access Strategy

From direct registration to strategic partnerships and tender submissions, we craft localized access strategies tailored to each market’s procurement and reimbursement landscape maximizing reach and patient access.

Competitor & Market Landscape Analysis

Gain strategic advantage through deep market intelligence. We benchmark competitors, pricing, and access conditions to inform your positioning and differentiate your product in crowded or emerging markets.

Stakeholder Engagement & Value Communication

Our consultants facilitate engagement with national and regional key decision makers including HTA bodies, payers, and Key Opinion Leaders (KOLs) by shaping compelling value narratives to support market access, drive decisions and address unmet needs.

Clinical trial medical device

Market Access Consulting for Medical Devices, IVDs & Veterinary Products

Market access consulting for medical devices, IVDs, and veterinary products includes full regulatory support, strategic planning, and post-approval data generation to drive patient access and commercial success.

Regulatory Approval

We secure registration from national authorities such as the NMPA in China and the HSA in Singapore.

Procurement Listing

We help you gain access through inclusion in public and private procurement systems across Asia Pacific.

Real World Evidence

We assist in post-market data collection and real-world performance tracking to support ongoing coverage and reimbursement.

Commercial Strategy

With our network of regional partners, we design contracting and distribution models that align with healthcare delivery and improve patient outcomes.

Market Access Consulting for Quasi-Drugs, Cosmetics, Ingredients, Health Foods, & Supplements

Our market access consulting services support clients targeting the complex and regulated markets of China, Hong Kong, Taiwan, South Korea, and Southeast Asia. We specialize in market access solutions for quasi-drug products, cosmetics, cosmetic ingredients, health foods, and dietary supplements, providing expert support for all compliance and certification needs.

Regulatory Compliance

We help you meet national requirements for product classification, labeling, safety, and claims. Whether you are registering a cosmetic in Taiwan, a health supplement in China, or a functional food in South Korea, our consultants ensure your product is ready for global market access and regional success.

Testing

We guide you through testing processes required across Asia Pacific to ensure your cosmetic or health food product is compliant, safe, and trusted. With our expert guidance, your products can meet all local standards and access regulated distribution channels while enhancing consumer trust and communicating your product’s value.

Market Access Consulting for Consumer Products & Industrial Goods

Our market access consulting services support clients targeting the complex and regulated markets of China, Hong Kong, Taiwan, South Korea, and Southeast Asia. We specialize in market access solutions for consumer and industrial products, providing expert support for all compliance and certification needs.

Regulatory Compliance

We help you meet national requirements for product classification, labeling, safety, and claims. Whether you are registering fire safety equipment in China, an electronic product in South Korea, or industrial components for export, our consultants ensure your product is ready for global market access and regional success.

Customs & Tariffs

We provide support in managing customs processes, tariffs, and regional trade agreements, helping you measure cost impacts, speed time-to-market, and maintain competitive pricing in global markets.

Certification & Testing

With our expert guidance, your products can meet all local standards and access regulated distribution channels while enhancing consumer trust and communicating your product’s value.

RoHS Compliance
Product Administrative License (PAL)
Network Access License (NAL)
Radio Transmission Equipment Certification (SRRC)
Korea Certification (KC)

With our expert guidance, your products can meet all local standards and access regulated distribution channels while enhancing consumer trust and communicating your product’s value.

Aktuelle Einblicke

Mehr anzeigen

Hong Kong Introduces Measures for Priority Approval of Innovative Medical Devices

Updated MDACS guidance creates a new pathway for qualifying technologies and outlines the evidence required for priority consideration.

August 3, 2026
Hong Kong Introduces Measures for Priority Approval of Innovative Medical Devices

CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

Explore the latest data on China’s clinical research landscape, including record trial activity, shorter development timelines, and emerging R&D trends.

August 3, 2026
CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

China Targets 65 Drugs in Its 12th National Procurement Round

The 12th national VBP round introduces tighter quality, manufacturing, and IP requirements that pharmaceutical companies must meet to compete.

August 3, 2026
China Targets 65 Drugs in Its 12th National Procurement Round

China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

New NMPA CDE guidelines define CTMP and GTMP boundaries, affecting development strategy, CMC planning, and regulatory engagement in China.

August 3, 2026
China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

China's 2026 Essential Medicines Adds More Innovative Drugs

China's updated National Essential Medicines List expands access to innovative medicines, creating new opportunities and strategic considerations for pharmaceutical companies.

August 3, 2026
China's 2026 Essential Medicines Adds More Innovative Drugs
A middle-aged man with glasses is looking down thoughtfully as he pours medication or pills from a small white bottle with a yellow label into his open palm.

China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications

China's NMPA expands priority review eligibility for chemical API marketing authorization applications, supporting domestic API production and drug supply.

August 3, 2026
China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications
Chemical API Manufacturing
Zurück
Zurück

Get in Touch with Our China Experts

Speak with our specialists to explore how our access consulting, regulatory services, and operational support can help your company succeed in the region’s evolving market access landscape.

Angebot anfordern